Role of centralized review processes for making reimbursement decisions on new health technologies in Europe

References

• MittonCDonaldsonCHealth care priority setting: Principles, practice and challengesCost Eff Resour Alloc200423815104792
   PubMedGoogle Scholar
• The health of Canadians: The federal role. Final report. Volume 6: Recommendations for reformOttawa, ONGovernment of Canada, Standing Senate Committee on Social Affairs2002 Available from: http://www.parl.gc.ca/Content/SEN/Committee/372/soci/rep/repoct02vol6-e.htm. Accessed July 22, 2011.
   Google Scholar
• WilkingNJonssonBA pan-European comparison regarding patient access to cancer drugsStockholm, SwedenKarolinska Institutet2006 Available from: http://ki.se/content/1/c4/33/52/Cancer_Report.pdf. Accessed March 13, 2011.
   Google Scholar
• StafinskiTMenonDPhilipponDJMcCabeCHealth technology funding decision-making processes around the world the same, yet differentPharmacoeconomics20112912121142275
   PubMed Web of Science ®Google Scholar
• Organization for Economic Cooperation and DevelopmentHealth Technologies and Decision MakingParis, FranceOrganization for Economic Cooperation and Development2005
   Google Scholar
• von der SchulenburgJVauthCMittendorfTGreinerWMethods for determining cost-benefit ratios for pharmaceuticals in GermanyEur J Health Econ20078Suppl 1S5S3117582539
   PubMed Web of Science ®Google Scholar
• ChalkidouKComparative effectiveness review within the UK’s National Institute for Health and Clinical ExcellenceIssue Brief (Commonw Fund)2009 Available from: http://www.commonwealthfund.org/~/media/Files/Publications/Issue%20Brief/2009/Jul/Chalkidou/1296_Chalkidou_UK_CER_issue_brief_717.pdf. Accessed July 18, 2011.
   Google Scholar
• Institute for Quality and Efficiency in Health CareGeneral methodsCologne, GermanyInstitute for Quality and Efficiency in Health Care2008 Available from: http://www.iqwig.net/methods-procedures.926.en.html. Accessed July 15, 2011.
   Google Scholar
• Van WilderPBDupontAGReimbursement of medicines in Belgium: Role of evidence-based medicineActa Clin Belg20096412012819432024
   PubMed Web of Science ®Google Scholar
• International Society for Pharmacoeconomics and Outcomes ResearchPharmacoeconomic guidelines around the world: SpainLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2010 Available from: http://www.ispor.org/PEguidelines/countrydet.asp?c=20&t=4. Accessed July 22, 2011.
   Google Scholar
• CleemputIVanWPHuybrechtsMVrijensFBelgian methodological guidelines for pharmacoeconomic evaluations: Toward standardization of drug reimbursement requestsValue Health20091244144919900251
   PubMed Web of Science ®Google Scholar
• GreinerWKuhlmannASchwarzbachCAn economic evaluation of the IQWiGs efficient frontierGesundheitsokonomie und Qualitatsmanagement201015241250 German.
   Google Scholar
• Guide to the multiple technology appraisal processLondon, UKNational Insitute for Health and Clinical Excellence2009 Available from: http://www.nice.org.uk/media/916/6B/Guide_to_the_MTA-proof_8-26-10-09.pdf. Accessed July 15, 2011.
   Google Scholar
• FaulknerEMatuszewskiKNiziolCISPOR global health care systems road map: SwedenLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2009 Available from: http://www.ispor.org/HTARoadMaps/Sweden.asp. Accessed July 15, 2011.
   Google Scholar
• Guidelines for companies: The Swedish Pharmaceutical Benefits Board (LFN)Stockholm, SwedenSwedish Pharmaceutical Benefits Board2008 Available from: http://www.tlv.se/Upload/English/Guidelines-for-Companies.pdf. Accessed July 15, 2011.
   Google Scholar
• Le PenCPricing and reimbursement policies in France: Current and future trendsGarauMMestre-FerrandizJEuropean Medicines Pricing and ReimbursementMilton Keynes, UKRadcliffe Publishing2007 Available from: http://www.radcliffe-oxford.com/books/samplechapter/184X/Garau_CHPT1-5e62f200rdz.pdf. Accessed July 22, 2011.
   Google Scholar
• CleemputIvan WilderPVVrijensFHuybrechtsMRamaekersDGuidelines for Pharmacoeconomic Evaluations in Belgium [KCE Reports 78C]Brussels, BelgiumBelgian Health Care Knowledge Centre2008 Available from: www.kce.fgov.be/Download.aspx?ID=1081. Accessed July 15, 2011.
   Google Scholar
• NasserMSawickiPInstitute for quality and efficiency in health care: GermanyIssue Brief (Commonw Fund)200957112 Available from: http://www.commonwealthfund.org/~/media/Files/Publications/Issue%20Brief/2009/Jul/Chalkidou/1294_Nasser_CER_Germany_issue_brief_724.pdf. Accessed July 15, 2011.19639711
   PubMedGoogle Scholar
• The Federal Joint Committee: About usBerlin, GermanyGemeinsamer Bundesausschuss, Institut fur Qualitat und Wirtschaftlichkeit in Gesundheitswesen2010 Available from: http://www.g-ba.de/downloads/17-98-2804/2010-01-01-Faltblatt-GBA_engl.pdf. Accessed July 15, 2011.
   Google Scholar
• RochaixLXerriBNational Authority for Health: France. Issue Brief (Commonw Fund). 2009;58]New YorkThe Commonwealth Fund2009 Available from: http://www.commonwealthfund.org/Content/Publications/Issue-Briefs/2009/Jul/National-Authority-for-Health-France.aspx. Accessed July 15, 2011.
   Google Scholar
• HablCAntonyKArtsDSurveying, assessing and analysing the pharmaceutical sector in the 25 EU member states: Country profilesViennaEuropean Commission; Osterreichisches Bundesinstitut fur Gesundheitswesen2006 Available from: http://ec.europa.eu/competition/mergers/studies_reports/oebig.pdf. Accessed July 15, 2011.
   Google Scholar
• ChicoyeALevesqueKISPOR global health care systems road map: France – Medical devicesLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2010 Available from : http://www.ispor.org/htaroadmaps/FranceMD.asp. July 15, 2011.
   Google Scholar
• SermetCAndrieuVGodmanBVanGEHaycoxAReynierJPOngoing pharmaceutical reforms in France: Implications for key stakeholder groupsAppl Health Econ Health Policy2010872420038190
   PubMedGoogle Scholar
• General methods for the assessment of the relation of benefits to costs. Version 1.0Cologne, GermanyInstitute for Quality and Efficiency in Health Care2009 Available from: http://www.iqwig.de/download/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Costs.pdf. Accessed July 15, 2011.
   Google Scholar
• Criteria for ranking therapeutic innovation of new drugs and elements for supplementing the dossier for admission to the reimbursement systemRome, ItalyAIFA – Italian Medicines Agency. Working Group on Innovative Drugs2007 Available from: http://www.agenziafarmaco.gov.it/allegati/integral_document.pdf. Accessed July 15, 2011.
   Google Scholar
• SorensonCUse of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparisonIssue Brief (Commonw Fund)201091New YorkThe Commonwealth Fund 2010. Available from: http://www.commonwealthfund.org/~/media/Files/Publications/Issue%20Brief/2010/Jul/1420_Sorenson_Comp_Effect_intl_ib_71.pdf. Accessed July 15, 2011.
   Google Scholar
• Lo ScalzoADonatiniAOrzellaLCicchettiAProfiliSMaressoAItaly: Health system review [Health Systems in Transition] CopenhagenDenmarkEuropean Observatory on Health Care Systems, World Health Organization Regional Office for Europe2009 Available from: http://www.euro.who.int/__data/assets/pdf_file/0006/87225/E93666.pdf. Accessed July 15, 2011.
   Google Scholar
• All Wales Medicines Strategy GroupVale of Glamorgan (Wales): Welsh Medicines Partnership2010 Available from: http://www.wales.nhs.uk/sites3/home.cfm?orgid=371. Accessed July 15, 2011.
   Google Scholar
• Guide to the single technology appraisal (STA) processLondon, UKNational Insitute for Health and Clinical Excellence (NICE)2009 Available from: http://www.nice.org.uk/media/913/06/Guide_to_the_STA-proof_6-26-10-09.pdf. Accessed July 15, 2011.
   Google Scholar
• Guidance to manufacturers for completion of new product assessment form (NPAF). Revised June 2010Glasgow, ScotlandScottish Medicines Consortium2010 Available from: http://www.scottishmedicines.org.uk/files/submissionprocess/New_Product_Assessment_Form_NPAF_Guidance_Notes_updated_February_2011_Final.doc. Accessed July 22, 2011.
   Google Scholar
• ZuidbergCPharmaceutical Pricing and Reimbursement Information. The pharmaceutical system of the NetherlandsVienna, Austria2010 Available from: http://ppri.oebig.at/Downloads/Publications/The%20pharmaceutical%20system%20of%20the%20Netherlands_FINAL.pdf. Accessed July 15, 2011.
   Google Scholar
• DanielsNSabinJELast chance therapies and managed care. Pluralism, fair procedures, and legitimacyHastings Cent Rep19982827419589291
   PubMed Web of Science ®Google Scholar
• SjogrenEDeciding subsidy for pharmaceuticals based on ambiguous evidenceJ Health Organ Manag20082236838318950073
   PubMedGoogle Scholar
• Pharmaceutical pricing and reimbursement information: NorwayVienna, AustriaPharmaceutical Pricing and Reimbursement Information2008 Available from: http://ppri.oebig.at/Downloads/Results/Norway_PPRI_2008.pdf. Accessed July 15, 2011.
   Google Scholar
• SorensonCDrummondMKanavosPEnsuring value for money in health care: the role of health technology assessment in the European Union [European Observatory on Health Systems and Policies Observatory Studies Series No 11]Copenhagen, DenmarkWorld Health Organization Regional Office for Europe2008 Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdf. Accessed July 15, 2011.
   Google Scholar
• TeixeiraIAgostinhoIPharmaceutical pricing and reimbursement informationLisbon, PortugalPharmaceutical Pricing and Reimbursement Information2008 Available from: http://www.infarmed.pt/portal/page/portal/INFARMED/MONITORIZACAO_DO_MERCADO/OBSERVATORIO/Projectos_Internacionais/Portugal_PPRI_2008.pdf. Accessed July 15, 2011.
   Google Scholar
• Appraising life-extending, end of life treatmentsLondon, UKNational Institute for Health and Clinical Excellence (NICE)2009 Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/endoflifetreatments.jsp. Accessed July 15, 2011.
   Google Scholar
• Guidelines for application for general reimbursement of medicinal productsCopenhagen, DenmarkThe Danish Medicines Agency2008 Available from: http://laegemiddelstyrelsen.dk/~/media/31C93DCD939A43FBB9E20070B5548337.ashx. Accessed July 22, 2011.
   Google Scholar
• 2000/030 summary of the appeals processLondon, UKNational Insitute for Health and Clinical Excellence (NICE)2000 Available from: http://www.nice.org.uk/newsroom/pressreleases/pressrelease-archive/pressreleases2000/2000_030_summary_of_the_appeals_process.jsp. Accessed January 7, 2010.
   Google Scholar
• StafinskiTMcCabeCJMenonDFunding the unfundable: Mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systemsPharmacoeconomics20102811314220085389
   PubMed Web of Science ®Google Scholar
• AdamskiJGodmanBOfierska-SujkowskaGRisk sharing arrangements for pharmaceuticals: Potential considerations and recommendations for European payersBMC Health Serv Res201010153 Available from: http://www.biomedcentral.com/1472-6963/10/153. Accessed July 15, 2011.20529296
   PubMed Web of Science ®Google Scholar
• GarnerSHow does NICE value innovation?Drug Dev Res201071449456
   Web of Science ®Google Scholar
• GrandfilsNDrug price setting and regulation in France [Working paper no. 16]Paris, FranceInstitut de recherche et documentation en economie de la sante (IRDES)2008 Available from: http://www.irdes.fr/EspaceAnglais/Publications/WorkingPapers/DT16DrugPriceSettingRegulationFrance.pdf. Accessed July 15, 2011.
   Google Scholar
• BarrosPPde Almeida SimoesJAllinSMossialosEPortugal: Health system review [Health Systems in Transition 2007;9(5)]Copenhagen, DenmarkWorld Health Organization Regional Office for Europe. European Observatory on Health Systems and Policies2007 Available from: http://www.euro.who.int/data/assets/pdf_file/0004/107842/E90670.pdf. Accessed July 15, 2011.
   Google Scholar
• BriggsARitchieKFenwickEChalkidouKLittlejohnsPAccess with evidence development in the UK: Past experience, current initiatives and future potentialPharmacoeconomics20102816317020085392
   PubMed Web of Science ®Google Scholar
• The Danish Medicines Agency: ReimbursementCopenhagen, DenmarkThe Danish Medicines Agency2010 Available from: http://laegemiddelstyrelsen.dk/en/topics/statistics,-prices-and-reimbursement/reimbursement-of-medicines. Accessed July 22, 2011.
   Google Scholar
• TonarelliLItaly: Pioneering pay for performance in the age of austerity. InPharm News(InPharm com) 2011 Available from: http://www.inpharm.com/news/110104/italy-drug-price-cuts. Accessed July 22, 2011.
   Google Scholar
• TowseAValue based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?Br J Clin Pharmacol20107036036620716236
   PubMed Web of Science ®Google Scholar
• Le PolainMFrankenMKoopmanschapMCleemputIDrug reimbursement systems: International comparison and policy recommendations. BrusselsBelgiumBelgian Health Care Knowledge Centre2010 Available from: http://www.kce.fgov.be/index_en.aspx?SGREF=5211&CREF=18732. Accessed July 22, 2011.
   Google Scholar
• Guidelines on procedure for reassessment of reimbursement statusCopenhagen, DenmarkDanish Medicines Agency2005 Available from: http://laegemiddelstyrelsen.dk/en/topics/statistics,-prices-and-reimbursement/reimbursement-of-medicines/general-reimbursement/reassessment-of-reimbursement-status-for-l-products/guidelines/guidelines-on-procedure-for-reassessment-ent-status. Accessed July 22, 2011.
   Google Scholar
• Welcome to TLV [the Dental and Pharmaceutical Benefits Agency]Stockholm, SwedenDental and Pharmaceutical Benefits Agency2008 Available from: http://www.tlv.se/in-english-old/in-english/. Accessed July 22, 2011.
   Google Scholar
• McLaughlinNOf problems and solutions. Issues with variable-rate bonds, medical errors led our recent coverageMod Healthc20093918
   Google Scholar
• McCabeCJStafinskiTEdlinRMenonDAccess with evidence development schemes: A framework for description and evaluationPharmacoeconomics20102814315220085390
   PubMed Web of Science ®Google Scholar
• MenonDMcCabeCJStafinskiTEdlinRPrinciples of design of access with evidence development approaches: A consensus statement from the Banff SummitPharmacoeconomics20102810911120085388
   PubMed Web of Science ®Google Scholar
• BuchholzPISPOR global health care systems road map: Austria – PharmaceuticalsLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2009 Available from: http://www.ispor.org/htaroadmaps/Austria.asp. Accessed July 23, 2011.
   Google Scholar
• GodmanBBucsicsABurkhardtTHaycoxASeyfriedHWieningerPInsight into recent reforms and initiatives in Austria: Implications for key stakeholdersExpert Rev Pharmacoecon Outcomes Res2008835737120528343
   PubMedGoogle Scholar
• WildCAustria: History of health technology assessment during the past 20 yearsInt J Technol Assess Health Care200925Suppl 1748119500437
   PubMed Web of Science ®Google Scholar
• Pharmaceutical pricing and reimbursement information: Austria [Pharmaceutical Pricing and Reimbursement Information]Vienna, AustriaEuropean Commission, Health and Consumer Protection Directorate-General and Austrian Ministry of Health, Family and Youth2008 Available from: http://ppri.oebig.at/Downloads/Results/Austria_PPRI_2008_Englih_Version.pdf. Accessed July 23, 2011.
   Google Scholar
• HofmarcherMMRackHMRohrlingGAustria: Health system review [Health Systems in Transition]Copenhagen, DenmarkEuropean Observatory on Health Care Systems, World Health Organization Regional Office for Europe2006 Available from: http://www.euro.who.int/__data/assets/pdf_file/0009/96435/E89021.pdf. Accessed July 23, 2011.
   Google Scholar
• Van WilderPBDupontAGReimbursement of medicines in Belgium: Role of evidence-based medicineActa Clin Belg20096412012819432024
   PubMed Web of Science ®Google Scholar
• CleemputIvanWPHuybrechtsMVrijensFBelgian methodological guidelines for pharmacoeconomic evaluations: Toward standardization of drug reimbursement requestsValue Health20091244144919900251
   PubMed Web of Science ®Google Scholar
• BelgiumPolicies for rare diseases and orphan drugs [KCE reports 112C]Brussels, BelgiumBelgian Health Care Knowledge Centre2009 Available from: http://www.kce.fgov.be/Download.aspx?ID=2161. Accessed July 23, 2011.
   Google Scholar
• Arrete royal portant modification de l’arrete royal du 3 juillet 1996 portant execution de la loi relative a l’assurance obligatoire soins de sante et indemnites, coordonnee le 14 juillet 1994[Brussels]Ministere des Affaires Sociales de la Sante Publique et de l’Environnement2001 Available from: http://www.inami.fgov.be/drug/fr/drugs/reglementation/legal-texts/pdf/arkb20011221.pdf. Accessed July 23, 2011.
   Google Scholar
• CorensDBelgium: Health system review [Health Systems in Transition 2007;9(2)]Copenhagen, DenmarkWorld Health Organization Regional Office for Europe. European Observatory on Health Care Systems2007 Available from: http://www.euro.who.int/__data/assets/pdf_file/0007/96442/E90059.pdf. Accessed July 23, 2011.
   Google Scholar
• Prices and reimbursements of medicinal products and foods for special medical purposesPrague, CzechoslovakiaState Institute for Drug Control2010 Available from: http://www.sukl.eu/sukl/prices-and-reimbursements-of-medicinal-products-and-foods. Accessed July 23, 2011.
   Google Scholar
• BryndovaLPavlokovaKRoubalTRokosovaMGaskinsMCzech Republic: Health system review [Health Systems in Transition 2009;11(1)]Copenhagen, DenmarkWorld Health Organization. Regional Office for Europe. European Observatory on Health Systems and Policies2009 Available from: http://www.euro.who.int/__data/assets/pdf_file/0010/97633/E92968.pdf. Accessed July 23, 2011.
   Google Scholar
• PraznovcovaLSuchoparJWertheimerAIDrug policy in the Czech RepublicWertheimerAISmithMCInternational Drug Regulatory MechanismsBinghamton, NYHaworth Press2003
   Google Scholar
• Pricing and reimbursement in DenmarkCopenhagen, DenmarkThe Danish Association of the Pharmaceutical Industry2007 Available from: http://parno1.ipapercms.dk/LIF/Notater/PricingandreimbursementinDenmark/. Accessed July 23, 2011.
   Google Scholar
• Strandberg-LarsenMKnudsenMSISPOR Global Health Care Systems Road Map: DenmarkLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2009 Available from: http://www.ispor.org/htaroadmaps/Denmark.asp. Accessed July 23, 2011.
   Google Scholar
• High quality care for all. NHS next stage review final reportLondon, UKDepartment of Health2008 Available from: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_085828.pdf. Accessed July 23, 2011.
   Google Scholar
• PedersenKMChristiansenTBechMThe Danish health care system: Evolution – not revolution – in a decentralized systemHealth Econ200514Suppl 1S41S5716170792
   PubMed Web of Science ®Google Scholar
• KanavosPVandorosSHabichtJde JoncheereKReview of the Estonian pharmaceutical sector: towards the development of a national medicines policyCopenhagen, DenmarkWorld Health Organization Regional Office for Europe2009 Available from: http://www.euro.who.int/__data/assets/pdf_file/0004/96448/E93049.pdf. Accessed July 15, 2011.
   Google Scholar
• Decree of the Ministry of Social Affairs and Health on the priced services of the Pharmaceuticals Pricing BoardHelsinki, FinlandFinland Ministry of Social Affairs and Health2010 Available from: http://www.stm.fi/c/document_library/get_file?folderId=71837&name=DLFE-14601.pdf. Accessed July 23, 2011.
   Google Scholar
• Decree of the Ministry of Social Affairs and Health on applications and price notifications made to the Pharmaceuticals Pricing BoardHelsinki, FinlandFinland Ministry of Social Affairs and Health2009 Available from: http://www.ispor.org/PEguidelines/source/Guidelines-inFinland_EnglishVersion.pdf. Accessed July 23, 2011.
   Google Scholar
• Pharmaceuticals Pricing Board: The expert group of the Pharmaceuticals Pricing BoardHelsinki, FinlandMinistry of Social Affairs and Health2010 Available from: http://www.stm.fi/en/ministry/boards/pharmaboard/expert. Accessed July 23, 2011.
   Google Scholar
• Ministry of Social Affairs and Health, FinlandDecree of the Ministry of Social Affairs and Health on applications and price notifications made to the Pharmaceuticals Pricing BoardHelsinki, FinlandMinistry of Social Affairs and Health, Finland2009 Available from: http://www.ispor.org/PEguidelines/source/GuidelinesinFinland_EnglishVersion.pdf. Accessed July 23, 2011.
   Google Scholar
• BeckerCFew details on DRG revamp. The CMS may reveal portions of new system in AprilModern Healthc20061112
   Google Scholar
• FalissardBIzardVXerriBBouvenotGMeyerFDegosLRelative effectiveness assessment of listed drugs (REAL): A new method for an early comparison of the effectiveness of approved health technologiesInt J Technol Assess Health Care20102612413020059790
   PubMed Web of Science ®Google Scholar
• WeillCBantaDDevelopment of health technology assessment in FranceInt J Technol Assess Health Care200925Suppl 110811119534838
   PubMed Web of Science ®Google Scholar
• ChicoyeAChhabraAISPOR global health care systems road map: France – PharmaceuticalsLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research (ISPOR)2009 Available from: http://www.ispor.org/htaroadmaps/France.asp. Accessed July 23, 2011.
   Google Scholar
• Pharmaceutical pricing and reimbursement information: GermanyVienna, AustriaPharmaceutical Pricing and Reimbursement Information2008 Available from: http://ppri.oebig.at/Downloads/Results/Germany_PPRI_2008.pdf. Accessed July 23, 2011.
   Google Scholar
• ParisVDocteurEPharmaceutical pricing and reimbursement policies in Germany [OECD Health Working Papers No. 39]Paris, FranceOrganisation for Economic Co-operation and Development2008 Available from: http://www.oecd.org/dataoecd/6/57/41586814.pdf. Accessed July 23, 2011.
   Google Scholar
• FrickeFUDaubenHPHealth technology assessment: A perspective from GermanyValue Health200912Suppl 2S20S2719523181
   PubMed Web of Science ®Google Scholar
• SorensonCThe role of HTA in coverage and pricing decisions: A cross-country comparisonEuro Observer: The Health Policy Bulletin of the European Observatory on Health Systems and Policies200911112 Available from: http://www.euro.who.int/__data/assets/pdf_file/0019/80335/EuroOb-server_spring2009.pdf. Accessed July 23, 2011.
   Google Scholar
• Pricing [Greece]Surveying, assessing and analysing the pharmaceutical sector in the 25 EU member statesLuxembourgOsterreichisches Bundesinstitut fur Gesundheitswesen for the European Commission2006 Available from: http://ec.europa.eu/competition/mergers/studies_reports/oebig.pdf. Accessed July 23, 2011.
   Google Scholar
• National Organization for MedicinesAthens, GreeceNational Organization for Medicines2011 Available from: http://www.eof.gr/web/guest/structure. Accessed July 23, 2011.
   Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research global health care systems road map: GreeceLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2008 Available from: http://www.ispor.org/HTARoadMaps/Greece.asp. Accessed July 23, 2011.
   Google Scholar
• GaalPHealth care systems in transition: HungaryBrussels, BelgiumEuropean Observatory on Health Care Systems2004 Available from: http://www.euro.who.int/__data/assets/pdf_file/0008/80783/E84926.pdf. Accessed July 23, 2011.
   Google Scholar
• GulacsiLDavidTDozsaCPricing and reimbursement of drugs and medical devices in HungaryEur J Health Econ2002327127815609154
   PubMedGoogle Scholar
• GulacsiLBrodszkyVPentekMVargaSVasGBonczIHistory of health technology assessment in HungaryInt J Technol Assess Health Care200925Suppl 112012619500441
   PubMed Web of Science ®Google Scholar
• TilsonLO’LearyAUsherCBarryMPharmacoeconomic evaluation in Ireland: A review of the processPharmacoeconomics20102830732220222754
   PubMed Web of Science ®Google Scholar
• BarryMEconomies in drug usage in the Irish healthcare settingDublin, IrelandDepartment of Health and Children2009 Available from: http://www.dohc.ie/publications/pdf/economies_drug_usage.pdf?direct=1. Accessed July 23, 2011.
   Google Scholar
• CoughlanJJFortescue-WebbDHeaneyRJudgeGTilsonLBarryMISPOR global health care systems road map: Ireland – PharmaceuticalLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2009 Available from: http://www.ispor.org/HTARoadMaps/Ireland.asp. Accessed July 23, 2011.
   Google Scholar
• GarattiniLPricing and reimbursement policies in Italy: Current and future trendsGarauMMestre-FerrandizJEuropean Medicines Pricing and ReimbursementMilton Keynes, UKRadcliffe Publishing2007 Available from: http://www.radcliffe-oxford.com/books/samplechapter/184X/Garau_CHPT4-65cf3e00rdz.pdf. Accessed July 23, 2011.
   Google Scholar
• Folino-GalloPMontillaSBruzzoneMMartiniNPricing and reimbursement of pharmaceuticals in ItalyEur J Health Econ2008930531018566845
   PubMed Web of Science ®Google Scholar
• Impact of HTA on policy: Examples from INAHTA membersStockholm, SwedenInternational Network of Agencies for Health Technology Assessment2001 Available from: http://www.inahta.org/upload/About%20INAHTA/Survey_HTA_Policy_Oct2001.pdf. Accessed July 23, 2011.
   Google Scholar
• FattoreGJommiCThe last decade of Italian pharmaceutical policy: Instability or consolidation?Pharmacoeconomics20082651518088155
   PubMed Web of Science ®Google Scholar
• JohnsenJRHealth systems in transition: NorwayCopenhagenWorld Health Organization Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies2006 Available from: http://www.euro.who.int/__data/assets/pdf_file/0005/95144/E88821.pdf. Accessed July 23, 2011.
   Google Scholar
• KuszewskiKGerickeCHealth systems in transition: Poland [Health Systems in Transition 2005;7(5)]Brussels, BelgiumEuropean Observatory on Health Care Systems2005 Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/95159/E88670.pdf. Accessed July 23, 2011.
   Google Scholar
• ISPOR global health care systems road map: Poland – reimbursement processLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2008 Available from: http://www.ispor.org/HTARoadMaps/Poland.asp. Accessed July 23, 2011.
   Google Scholar
• Alves da SilvaEGouveia PintoCSampaioCPereiraJADrummondMTrindadeRGuidelines for economic drug evaluation studiesLisbon, PortugalAutoridade Nacional do Medicamento e Produtos de Saude1998 Available from: http://www.infarmed.pt/portal/page/portal/INFARMED/ENGLISH/PCAEC04_vering.pdf. Accessed July 23, 2011.
   Google Scholar
• MazagJSegecAPharmaceutical pricing and reimbursement information: Slovakia [Pharmaceutical Pricing and Reimbursement Information]Vienna, AustriaEuropean Commission, Health and Consumer Protection Directorate-General; Austrian Ministry of Health, Family and Youth2007 Available from: http://ppri.oebig.at/Downloads/Results/Slovakia_PPRI_2007.pdf. Accessed July 23, 2011.
   Google Scholar
• HallPSMcCabeCBrownJMCameronDAHealth economics in drug development: Efficient research to inform healthcare funding decisionsEur J Cancer2010462674268020655197
   PubMed Web of Science ®Google Scholar
• KohliHTannahillANICE guidance in the Scottish contextScott Med J2009543538 Available from: http://www.smj.org.uk/0209/pdfs/Original%20Kohli%20and%20Tannahill.pdf. Accessed July 23, 2011.19291935
   PubMed Web of Science ®Google Scholar
• TomekDPsenkovaMHanzelovaMReimbursement of innovative drugs in Slovakia – pharmacoeconomics of agomelatin in depressionValue Health200912A364A365
   Web of Science ®Google Scholar
• KaloZDocteurEMoisePPharmaceutical pricing and reimbursement policies in Slovakia [OECD Health Working Paper No. 31]Paris, FranceOrganisation for Economic Co-operation and Development2008 Available from: http://www.oecd.org/dataoecd/14/40/40177050.pdf. Accessed July 23, 2011.
   Google Scholar
• SzalayTPazitnyPSzalayovaASlovakia: Health system review [Health Systems in Transition 2011;13(2)]Copenhagen, DenmarkWorld Health Organisation Regional Office for Europe. European Observatory on Health Systems and Policies2011 Available from: http://www.euro.who.int/__data/assets/pdf_file/0004/140593/e94972.pdf. Accessed July 23, 2011.
   Google Scholar
• VoglerSEspinJHablCPharmaceutical pricing and reimbursement information (PPRI) – new PPRI analysis including SpainPharm Pol Law200911213234 Available from: http://ppri.oebig.at/Downloads/Publications/Article_PPRI_Spain_PharmaceuticalPolicyAndLaw_2009.pdf. Accessed July 23, 2011.
   Google Scholar
• PerssonUWillisMOdegaardKA case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in SwedenEur J Health Econ20101119520319639352
   PubMed Web of Science ®Google Scholar
• MoisePDocteurEPharmaceutical pricing and reimbursement policies in Sweden [OECD Health Working Papers, No. 28]Paris, FranceOrganisation for Economic Co-operation and Development (OECD)2007 Available from: http://www.oecd.org/dataoecd/63/17/40699881.pdf. Accessed July 23, 2011.
   Google Scholar
• Pharmaceutical Pricing and Reimbursement Information: SwedenVienna, AustriaPPRI – Pharmaceutical Pricing and Reimbursement Information2007 Available from: http://ppri.oebig.at/Downloads/Results/Sweden_PPRI_2007.pdf. Accessed July 23, 2011.
   Google Scholar
• ErntoftSISPOR global health care systems road map: Sweden – pharmaceuticalLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2009 Available from: http://www.ispor.org/HTARoadMaps/Sweden.asp. Accessed July 23, 2011.
   Google Scholar
• GressSNiebuhrDMayWWasemJReform of prescription drug reimbursement and pricing in the German social health insurance market: A comparison of three scenariosPharmacoeconomics20072544345417523750
   PubMed Web of Science ®Google Scholar
• ParisVDocteurEPharmaceutical pricing and reimbursement policies in Switzerland [OECD Health Working Papers, No. 27]Paris, FranceOrganisation for Economic Co-operation and Development (OECD)2007 Available from: http://www.oecd.org/dataoecd/54/42/38868953.pdf. Accessed July 23, 2011.
   Google Scholar
• European Observatory on Health Care SystemsHealth care systems in transition: SwitzerlandBrussels, BelgiumEuropean Observatory on Health Care Systems2000 Available from: http://www.euro.who.int/__data/assets/pdf_file/0003/96411/E68670.pdf. Accessed July 23, 2011.
   Google Scholar
• van der MeijdenCGrahlmannCDutch assessment procedures for the reimbursement of outpatient medicinesDiemen, The NetherlandsMinistry of Health, Welfare and Sport/College voor zorgverzekeringen2010 Available from: http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/rubriek+zorgpakket/cfh/assessment-outpatient-medicines.pdf. Accessed July 23, 2011.
   Google Scholar
• StolkEAde BontAvan HalterenARBijlmerRJPoleyMJRole of health technology assessment in shaping the benefits package in The NetherlandsExpert Rev Pharmacoecon Outcomes Res20099859419371181
   PubMedGoogle Scholar
• ISPOR global health care systems road map: The NetherlandsLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2007 Available from: http://www.ispor.org/HTARoadMaps/Netherlands.asp. Accessed July 23, 2011.
   Google Scholar
• HeemstraHEVariations in access and use of orphan drugs among EU member statesEJHP Practice2010162527 Available from: http://www.eahp.eu/EJHP/EJHP-Practice/Issue-4-2010/Cover-Story/Variations-in-access-and-use-of-orphan-drugs-among-EU-Member-States. Accessed July 23, 2011.
   Google Scholar
• ISPOR global health care systems road map: United Kingdom (England and Wales) – reimbursement processLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2008 Available from: http://www.ispor.org/htaroadmaps/UK.asp. Accessed July 23, 2011.
   Google Scholar
• The Danish Health Act/legislationCopenhagen, DenmarkDanish Medicines Agency2010 Available from: http://laegemiddelstyrelsen.dk/en/service-menu/legislation/the-danish-health-act. Accessed July 23, 2011.
   Google Scholar
• MossialosESrivastavaDPharmaceutical policies in Finland: Challenges and opportunities [Observatory Studies Series No 10]Copenhagen, DenmarkWorld Health Organisation. Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies2008 Available from: http://www.euro.who.int/__data/assets/pdf_file/0020/80651/E91239.pdf. Accessed July 23, 2011.
   Google Scholar
• PerlethMGibisBGohlenBA short history of health technology assessment in GermanyInt J Technol Assess Health Care200925Suppl 111211919500440
   PubMed Web of Science ®Google Scholar
• HoltorfAPMatuszewskiKNuijtenMVauthCISPOR global health care systems road map: GermanyLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2009 Available from: http://www.ispor.org/htaroadmaps/Germany.asp. Accessed July 23, 2011.
   Google Scholar
• TilsonLBarryMRecent developments in pharmacoeconomic evaluation in IrelandExpert Rev Pharmacoecon Outcomes Res20101022122420545585
   PubMed Web of Science ®Google Scholar
• Pricing and reimbursementRome, ItalyAgenzia Italiana del Farmaco2010 Available from: http://www.agenziafarmaco.it/en/content/pricing-and-reimbursement. Accessed July 23, 2011.
   Google Scholar
• Agencja Oceny Technologii MedycznychWarsaw, PolandAgencja Oceny Technologii Medycznych2011 Available from: http://www.aotm.gov.pl/. Accessed July 23, 2011.
   Google Scholar
• Scottish Medicines ConsortiumScottish Medicines Consortium2010 Available from: http://www.scottishmedicines.org.uk/smc/22.html. Accessed July 23, 2011.
   Google Scholar
• WilkingNJonssonBA pan-European comparison regarding patient access to cancer drugsStockholm, SwedenKarolinska Institutet2006 Available from: http://ki.se/content/1/c4/33/52/Cancer_Report.pdf. Accessed July 23, 2011.
   Google Scholar
• Informace k pravidelne revizi uhradPrague, CzechoslovakiaStatni Ustav pro Kontrolu Leciv (SUKL)2009 Available from: http://www.sukl.cz/leciva/informace-k-pravidelne-revizi-uhrad. Accessed July 23, 2011.
   Google Scholar
• TomekDBielikJLegislative aspects of health technology assessment in SlovakiaValue Health200912A87
   Web of Science ®Google Scholar
• ISPOR global health care systems road map: Spain – PharmaceuticalLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2009 Available from: http://www.ispor.org/HTARoadMaps/Spain.asp. Accessed July 23, 2011.
   Google Scholar
• Pharmaceutical Pricing and Reimbursement Information: SwedenVienna, AustriaPharmaceutical Pricing and Reimbursement Information2007 Available from: http://ppri.oebig.at/Downloads/Results/Sweden_PPRI_2007.pdf. Accessed July 23, 2011.
   Google Scholar
• Working guidelines for the pharmaceutical reimbursement reviewStockholm, SwedenTandvards-Och Lakemedelsformansverket (TLV)/the Dental and Pharmaceutical Benefits Agency [formerly the Swedish Pharmaceutical Benefits Board]2008 Available from: http://www.tlv.se/Upload/Genomgangen/guidelines-pharmaceutical-reimbursement.pdf. Accessed July 23, 2011.
   Google Scholar
• Reimbursement reviewStockholm, SwedenTandvards Och Lakemedelsformansverket (TLV) [The Swedish Pharmaceutical Benefits Board]2009 Available from: http://www.tlv.se/in-english/reimbursement-review/. Accessed July 23, 2011.
   Google Scholar
• GlenngardAHHjalteFSvenssonMAnellABankauskaiteVHealth systems in transition: SwedenCopenhagen, DenmarkWorld Health Organisation Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies2005 Available from: http://www.euro.who.int/__data/assets/pdf_file/0010/96409/E88669.pdf. Accessed July 23, 2011.
   Google Scholar
• GressSNiebuhrDRothgangHWasemJCriteria and procedures for determining benefit packages in health care. A comparative perspectiveHealth Policy200573789115911059
   PubMed Web of Science ®Google Scholar
• DolezalTPricing and reimbursement in Czech Republic ... road to HTA?Lawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2008 Available from: http://www.google.ca/url?sa=t&source=web&cd=2&ved=0CBwQFjAB&url=http%3A%2F%2Fwww.isporserbia.com%2Fdocs%2Ffirst%2FMarch10%2F02.ppt&ei=QgTkTfnFDqvQiAL0l7WoBg&usg=AFQjCNEcRD0RWYovvKcnIEV-017m4bG0ow. Accessed July 23,2011.
   Google Scholar
• Pharmacoeconomic analysisTallinn, EstoniaEstonian Health Insurance Fund2002 Available from: http://www.haigekassa.ee/eng/health-insurance-in-estonia/medicinal-products/pharmacoeconomic-analysis. Accessed July 23, 2011.
   Google Scholar
• AaviskooASaluseJPalmEScientific community leads HTA development [Health Policy Monitor]2009 Available from: http://www.hpm.org/survey/ee/a14/2. Accessed July 23, 2011.
   Google Scholar
• DanielsNSabinJLimits to health care: Fair procedures, democratic deliberation, and the legitimacy problem for insurersPhilos Public Aff19972630335011660435
   PubMed Web of Science ®Google Scholar
• BekkeringGEKleijnenJProcedures and methods of benefit assessments for medicines in GermanyEur J Health Econ20089Suppl 152918987905
   PubMed Web of Science ®Google Scholar
• MartikainenJRajaniemiSDrug reimbursement systems in EU member states, Iceland and Norway: France In. 54.HelsinkiThe Social Insurance Institution2002 Available from: http://www.kela.fi/in/internet/english.nsf/NET/050303135141PN. Accessed July 23, 2011.
   Google Scholar
• ParisVDocteurEPharmaceutical pricing and reimbursement policies in Germany [OECD Health Working Papers, No. 39]ParisOrganisation for Economic Co-operation and Development (OECD)2008 Available from: http://www.oecd.org/dataoecd/6/57/41586814.pdf. Accessed July 23, 2011.
   Google Scholar
• YfantopoulosJPharmaceutical pricing and reimbursement reforms in GreeceEur J Health Econ20089879717619920
   PubMed Web of Science ®Google Scholar
• Irish healthcare technology assessment guidelines. version 1Dublin, IrelandNational Centre for Pharmacoeconomics (NCPE) in Ireland2000 Available from: http://www.ncpe.ie/contact.php. Accessed July 23, 2011.
   Google Scholar
• Guidelines for the economic evaluation of health technologies in IrelandDublin, IrelandHealth Information and Quality Authority2010 Available from: http://www.hiqa.ie/system/files/HTA_Economic_Guidelines_2010.pdf. Accessed July 23, 2011.
   Google Scholar
• Pharmacoeconomic guidelines around the world: ItalyLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2010 Available from: http://www.ispor.org/PEguidelines/countrydet.asp?c=13&t=4. Accessed July 23, 2011.
   Google Scholar
• Application standard for acceptance to the drug reimbursement scheme; pursuant to Article 9 of the regulation on reimbursement of crucial drug costs[Oslo]Statens legemiddelverk/Norwegian Medicines Agency2005 Available from: http://www.legemiddelverket.no/templates/InterPage_25665.aspx. Accessed July 23, 2011.
   Google Scholar
• Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursementOslo, NorwayStatens legemid-delverk/Norwegian Medicines Agency2005 Available from: http://www.legemiddelverket.no/templates/InterPage_25644.aspx. Accessed July 23, 2011.
   Google Scholar
• Polish guidelines for conducting pharmacoeconomic evaluationsLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2010 Available from: http://www.ispor.org/PEguidelines/source/Polish-Guidelines-for-Conducting-Pharmacoeconomic-Evaluations_2010.pdf. Accessed July 23, 2011.
   Google Scholar
• Pharmacoeconomic guidelines around the world: Slovak RepublicLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2011 Available from: http://www.ispor.org/peguidelines/countrydet.asp?c=35&t=1. Accessed July 23, 2011.
   Google Scholar
• General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2)Stockholm, SwedenPharmaceutical Benefits Board2003 Available from: http://www.ispor.org/peguidelines/source/Guidelines_in_Sweden.pdf. Accessed July 23, 2011.
   Google Scholar
• VegterSRozenbaumMHPostemaRTolleyKPostmaMJReview of regulatory recommendations for orphan drug submissions in The Netherlands and Scotland: Focus on the underlying pharmacoeconomic evaluationsClin Ther2010321651166120974323
   PubMed Web of Science ®Google Scholar
• StolkEAPoleyMJCriteria for determining a basic health services package. Recent developments in The NetherlandsEur J Health Econ200562715700150
   PubMedGoogle Scholar
• StolkEAdeBAvan HalterenARBijlmerRJPoleyMJRole of health technology assessment in shaping the benefits package in The NetherlandsExpert Rev Pharmacoecon Outcomes Res20099859419371181
   PubMedGoogle Scholar
• Single technology appraisal (STA): Specification for manufacturer/sponsor submission of evidenceLondon, UKNational Institute for Health and Clinical Excellence2009 Available from: http://www.nice.org.uk/media/59C/B3/SpecificationForManufacturerSponsorSubmissionEvidenceJune2010.doc. Accessed July 23, 2011.
   Google Scholar
• LloydAWildDGallopKCowellWReimbursement agency requirements for health related quality-of-life data: A case studyExpert Rev Pharmacoecon Outcomes Res2009952753719941430
   PubMedGoogle Scholar
• NiemietzKPMPA healthy market? Health technology assessment in the UK and Germany [Stockholm Network Papers on Health Technology Assessment. Paper No. 2]Stockholm, SwedenStockholm Network2007 Available from: http://www.stockholm-network.org/downloads/publications/HTA3_2.pdf. Accessed July 23, 2011.
   Google Scholar
• BarrosPPPharmaceutical policies in European countriesAdv Health Econ Health Serv Res20102232720575226
   PubMedGoogle Scholar
• Annex to the decree by the Ministry of Social Affairs and Health on applications for a reasonable wholesale price, on special reimbursement status for a medicinal product, and on the documentation to be attached to the application (1393/2003)Helsinki, FinlandFinland Ministry of Social Affairs and Health2003 Available from: http://www.stm.fi/c/document_library/get_file?folderId=71837&name=DLFE-7603.pdf. Accessed July 23, 2011.
   Google Scholar
• Medical device assessment in France: GuidebookCedex, FranceHaute Autorite de Sante2009 Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/guide_dm_gb_050310.pdf. Accessed July 23, 2011.
   Google Scholar
• Office of Health Technology Assessment of the National Institute for Strategic Health ResearchBudapest, HungaryNational Institute for Strategic Health Research2011 Available from: http://www.eski.hu/new3/technologia_en/technologia_en.php. Accessed July 23, 2011.
   Google Scholar
• BrodszkyVOrlewskaEPentekMKarpatiKSkoupaJGulacsiLChallenges in economic evaluation of new drugs: Experience with rituximab in HungaryMed Sci Monit201016SR1SR520037504
   PubMed Web of Science ®Google Scholar
• BarryMTilsonLRecent developments in pricing and reimbursement of medicines in IrelandExpert Rev Pharmacoecon Outcomes Res20077605611 Available from: http://www.expert-reviews.com/doi/pdf/10.1586/14737167.7.6.605. Accessed July 23, 2011.20528322
   PubMedGoogle Scholar
• KozierkiewiczATrabkaWRomaszewskiAGajdaKGilewskiDDefinition of the “health benefit basket” in PolandEur J Health Econ20056Suppl 15865 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1388086/?tool=pubmed. Accessed July 23, 2011.16258749
   PubMedGoogle Scholar
• OrlewskaEMierzejewskiPProject of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelinesEur J Health Econ2003429630315609200
   PubMedGoogle Scholar
• Pharmacoeconomic guidelines around the world: ScotlandLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2010 Available from: http://www.ispor.org/PEguidelines/countrydet.asp?c=19&t=2. Accessed July 15, 2011.
   Google Scholar
• VisnanskyMHTA and health care decisions in SlovakiaLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2010 Available from: http://www.ispor.org/regional_chapters/Slovakia/documents/ISPOR_HTA_and_HC_Dcisions_in_SK_HTAC_112010.pdf. Accessed July 23, 2011.
   Google Scholar
• Guideline: the Ministry of Health of the Slovak Republic no. 343/2008 Z. z. the details of pharmaco-economic analysis of drug ... the Ministry of Health of the Slovak Republic no. 210/2008 Z. laws, which provides details on the medico-economic analysis of the medical device when the decree of the Ministry of Health of the Slovak Republic no. 149/2009 Z. z. the details of medico-economic analysis of dietary food for the implementation of pharmaco-economic analysis of drug; medico-econoic analysis of the medical device and medico-economic analysis of the dietary foodBratislava, SlovakiaMinisterstva zdravotnictva Slovenskej republiky2009 Available from: http://www2.health.gov.sk/redsys/rsi.nsf/0/4399FF0A33156D1CC1256FAF002B94DE?OpenDocument. Accessed July 23, 2011.
   Google Scholar
• DuranALaraJLvan WaverenMSpain: Health system review [Health Systems in Transition]Copenhagen, DenmarkEuropean Observatory on Health Care Systems, World Health Organization Regional Office for Europe2006 Available from: http://www.euro.who.int/en/home/projects/observatory/publications/health-system-profiles-hits/full-list-of-hits/spain-hit-2007. Accessed July 23, 2011.
   Google Scholar
• MullerKRISPOR global health care systems road map: Switzerland – PharmaceuticalLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research (ISPOR)2011 Available from: http://www.ispor.org/htaroadmaps/SwitzerlandPH.asp. Accessed July 23, 2011.
   Google Scholar
• van NootenFvan AgthovenMMandatory pharmacoeconomic studies in the Dutch reimbursement settingInstitute for Medical Technology Assessment newsletter2005313 Available from: http://www.bmg.eur.nl/fileadmin/ASSETS/bmg/english/iMTA/Publications/Newsletter/imta_newsletter_3_1.pdf. Accessed July 23, 2011.
   Google Scholar
• All Wales Medicines Strategy Group: Structure of appraisalVale of Glamorgan, WalesAll Wales Medicines Strategy Group2007 Available from: http://www.wales.nhs.uk/sites3/home.cfm?orgid=371. Accessed July 23, 2011.
   Google Scholar
• INAMI – medicamentsBrussels, BelgiumI National Institute for Health and Disability Insurance2011 Available from: http://www.inami.fgov.be/drug/fr/drugs/index.htm#2. Accessed July 23, 2011.
   Google Scholar
• SandmannFGFramework of decision making regarding the benefit package in the Czech RepublicDecision making on the inclusion of new provisions in the benefit package: A comparative study between the Netherlands and the Czech Republic (with a focus on the role of value for money considerations in pharmaceutical reimbursement decision making)Enschede, The NetherlandsUniversity of Twente. School of Management and Governance2010 Available from: http://www.utwente.nl/mb/htsr/education/completed%20assignments/Sandmann.pdf. Accessed July 23, 2011.
   Google Scholar
• PetrikovaADolezalTLamkaJKlimesJDescription of the pricing and reimbursement system in the Czech RepublicPrague, CzechoslovakiaInstitute of Health Economics and Technology Assessment2010 Available from: http://www.iheta.org/ext/files/27/Poster_ISPOR_PR_CZ.pdf. Accessed July 23, 2011.
   Google Scholar
• DavidovaJPraznovcovaLLundborgCSPricing and reimbursement of pharmaceuticals in the Czech Republic and SwedenPharm World Sci200830576417588212
   PubMedGoogle Scholar
• DavidovaJIvanovicNPraznovcovaLParticipation in pharmaceutical costs and seniors’ access to medicines in the Czech RepublicCent Eur J Public Health2008162628 Available from: http://www1.szu.cz/svi/cejph/archiv/2008-1-06-full.pdf. Accessed July 23, 2011.18459476
   PubMedGoogle Scholar
• SpacilovaLPetrelliFGrappasonniIScuriSHealth care system in the Czech RepublicAnn Ig20071957358118376578
   PubMedGoogle Scholar
• MossialosESrivastavaDOverview of the pharmaceutical system in FinlandPharmaceutical policies in Finland: challenges and opportunities [Observatory Studies Series No 10]Copenhagen, DenmarkWorld Health Organization; European Observatory on Health Systems and Policies; Ministry of Social Affairs and Health Finland2008 Available from: http://www.euro.who.int/__data/assets/pdf_file/0020/80651/E91239.pdf. Accessed July 23, 2011.
   Google Scholar
• Government decree on the Pharmaceuticals Pricing BoardHelsinki, FinlandFinland Ministry of Social Affairs and Health2008 Available from: http://www.stm.fi/c/document_library/get_file?folderId=71837&name=DLFE-10036.pdf. Accessed July 23, 2011.
   Google Scholar
• Strandberg-LarsenMNielsenMBVallgardaSKrasnikAVrangbaekKDenmark: Health system review [Health Systems in Transition 2007;9]Copenhagen, DenmarkWorld Health Organisation Regional Office for Europe. European Observatory on Health Care Systems2007 Available from: http://www.euro.who.int/__data/assets/pdf_file/0004/80581/E91190.pdf. Accessed July 23, 2011.
   Google Scholar
• FalissardBZylbermanMCucheratMReal medical benefit assessed by indirect comparisonTherapie200964225232 French.19671436
   PubMed Web of Science ®Google Scholar
• Haute Autorite de SanteCedex, FranceHaute Autorite de Sante2010 Available from: http://www.has-sante.fr. Accessed July 23, 2011.
   Google Scholar
• YfantopoulosJPharmaceutical pricing and reimbursement reforms in GreeceEur J Health Econ20089879717619920
   PubMed Web of Science ®Google Scholar
• Rules of procedure of the social insurance inclusion of pharmaceuticals in HungaryBudapest, HungaryNational Institute for Strategic Health Research. Office of Health Technology Assessment2011 Available from: http://www.eski.hu/new3/technologia_en/technologia_en_procedure.php. Accessed July 23, 2011.
   Google Scholar
• ISPOR global health care systems road map: Italy – PharmaceuticalsLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research (ISPOR)2011 Available from: http://www.ispor.org/HTARoadMaps/Italy.asp. Accessed July 23, 2011.
   Google Scholar
• GodmanBSakshaugSBergCWettermarkBHaycoxACombination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costsExpert Rev Pharmacoecon Outcomes Res20111112112921351864
   PubMed Web of Science ®Google Scholar
• NizankowskiRWilkNFrom idealistic rookies to a regional leader: The history of health technology assessment in PolandInt J Technol Assess Health Care200925Suppl 115616219527537
   PubMed Web of Science ®Google Scholar
• Ministerio da Saude: Decreto-Lei no. 48-A/2010Oeiras, PortugalAssociacao Portuguese de Medicamentos Genencos2010 Available from: http://www.apogen.pt/conteudos/uploads/Files/apogen/PacoteMedicamento_13Maiode2010.pdf. Accessed July 23, 2011.
   Google Scholar
• JanssonSImplementing accountability for reasonableness – the case of pharmaceutical reimbursement in SwedenHealth Econ Policy Law20072Pt 215317118634660
   PubMed Web of Science ®Google Scholar
• Guidelines for pharmacoeconomic research, updated versionDiemen, The NetherlandsCollege voor Zorgverzekeringen2006 Available from: http://www.ispor.org/peguidelines/source/HTAGuidelinesNLupdated2006.pdf. Accessed July 23, 2011.
   Google Scholar
• HealyPPugatchMTheory versus practice: Discussing the governance of health technology assessment systemsStockholm, SwedenStockholm Network2009 Available from: http://www.stockholm-network.org/downloads/publications/Theory_versus_Practice.pdf. Accessed July 23, 2011.
   Google Scholar
• SculpherMSingle technology appraisal at the UK National Institute for Health and clinical excellence: A source of evidence and analysis for decision making internationallyPharmacoeconomics20102834734920402539
   PubMed Web of Science ®Google Scholar
• KennedyIAppraising the value of innovation and other benefits: A short study for NICELondon, UKNational Institute for Health and Clinical Excellence2009 Available from: http://www.nice.org.uk/media/98F/5C/KennedyStudyFinalReport.pdf. Accessed July 23, 2011.
   Google Scholar
• RawlinsMDCulyerAJNational Institute for Clinical Excellence and its value judgmentsBMJ200432922422715271836
   PubMed Web of Science ®Google Scholar
• All Wales Medicines Strategy Group: Independent review processVale of Glamorgan, WalesAll Wales Medicines Strategy Group2007 Available from: http://www.wales.nhs.uk/sites3/Documents/371/Independent%20Review%20process%20_fina%20for%20website_.pdf. Accessed July 23, 2011.
   Google Scholar
• General method for assessing health technologiesParis, FranceHaute Autorite de Sante, Department of Medical and Surgical Procedures Assessment2007 Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/general_method_eval_techno.pdf. Accessed July 23, 2011.
   Google Scholar
• ISPOR global health care systems road map: Italy – Reimbursement processLawrenceville, NJInternational Society for Pharmacoeconomics and Outcomes Research2008 Available from: http://www.ispor.org/HTARoadMaps/Italy.asp. Accessed July 23, 2011.
   Google Scholar
• StolkEARuttenFFThe “health benefit basket” in the NetherlandsEur J Health Econ2005Suppl535716270209
   PubMedGoogle Scholar
• DevlinNParkinDDoes NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Econ20041343745215127424
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals Pricing Board: the Pharmaceuticals Pricing Board and the secretariatHelsinki, FinlandMinistry of Social Affairs and Health/Social – Och Halsovardsministeriet2009 Available from: http://www.stm.fi/en/ministry/boards/pharmaboard/board. Accessed July 23, 2011.
   Google Scholar
• NasserMSawickiPInstitute for quality and efficiency in health care: GermanyIssue Brief (Commonw Fund)200957112 Available from: http://www.commonwealthfund.org/~/media/Files/Publications/Issue%20Brief/2009/Jul/Chalkidou/1294_Nasser_CER_Germany_issue_brief_724.pdf. AccessedJuly 23, 2011.19639711
   PubMedGoogle Scholar
• VandorosSKanavosPPricing, regulation, reimbursement and health-care budgetsEuropean Cancer Patient Coalition2009 Available from: http://www.ecpc-online.org/component/docman/doc_download/121-sotiri-vandoros-pricing-regulation-reimbursement-and-healthcare-budgets.html?ItemId=127. Accessed July 23, 2011.
   Google Scholar
• PerssonUWillisMOdegaardKA case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in SwedenEur J Health Econ20101119520319639352
   PubMed Web of Science ®Google Scholar
• MoisePDocteurEPharmaceutical pricing and reimbursement policies in Sweden [OECD Health Working Papers, No. 28]Paris, FranceOrganisation for Economic Co-operation and Development (OECD)2007 Available from: http://www.oecd.org/dataoecd/63/17/40699881.pdf. Accessed July 23, 2011.
   Google Scholar
• JanssonSImplementing accountability for reasonableness – the case of pharmaceutical reimbursement in SwedenHealth Econ Policy Law20072Pt 215317118634660
   PubMed Web of Science ®Google Scholar
• WillisMPerssonUZoellnerYGradlBReducing uncertainty in value-based pricing using evidence development agreements: The case of continuous intraduodenal infusion of levodopa/carbidopa (DuodopaR) in SwedenAppl Health Econ Health Policy2010837738621043539
   PubMedGoogle Scholar
• StolkPSchneeweissSLeufkensHGMHeerdinkERImpact analysis of the discontinuation of reimbursement: The case of oral contraceptivesContraception20087839940418929737
   PubMed Web of Science ®Google Scholar
• SchaferWKronemanMBoermaWThe Netherlands: Health system review [Health Systems in Transition]Copenhagen, DenmarkEuropean Observatory on Health Care Systems, World Health Organization Regional Office for Europe2010 Available from: http://www.euro.who.int/en/home/projects/observatory/publications/health-system-profiles-hits/full-list-of-hits/netherlands-hit-2010. Accessed July 23, 2011.
   Google Scholar
• WebbDJValue-based medicine pricing: NICE work?Lancet20113771552155321093902
   PubMed Web of Science ®Google Scholar
• KanavosPManningJTaylorDSchurerWChecchiKImplementing value-based pricing for pharmaceuticals in the UK. Final reportLondon, UK2020 Health2010 Available from: http://www.2020health.org/2020health/research/vbp-a.html. Accessed July 23, 2011.
   Google Scholar
• A new value-based approach to the pricing of branded medicines: A consultationLondon, UKUK Department of Health. Medicines, Pharmacy and Industry Group2010 Available from: http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_122760. Accessed July 23, 2011.
   Google Scholar